- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, IO biomarker: Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies. (Pubmed Central) - Jan 13, 2021
Some of the most versatile therapeutic anti-EGFR agents include the monoclonal antibodies (mAbs), demonstrating success in clinical settings when used in combination with cytotoxic treatments, such as chemotherapy and/or radiation. We thus discuss the development and application of two of the most notable therapeutic mAbs, cetuximab and panitumumab, currently utilized in various EGFR-related epithelial cancers.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Bat IFITM3 restriction depends on S-palmitoylation and a polymorphic site within the CD225 domain. (Pubmed Central) - Jan 13, 2021
Furthermore, we show that microbat IFITM3 is S-palmitoylated on cysteine residues C71, C72, and C105, mutation of each cysteine individually impairs virus restriction, and a triple C71A-C72A-C105A mutant loses all restriction activity, concomitant with subcellular re-localization of microbat IFITM3 to Golgi-associated sites. Thus, we propose that S-palmitoylation is critical for Chiropteran IFITM3 function and identify a key molecular determinant of IFITM3 S-palmitoylation.
- |||||||||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial completion date, Metastases: BEACON CRC: Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 13, 2021
P3, N=702, Active, not recruiting,
Thus, we propose that S-palmitoylation is critical for Chiropteran IFITM3 function and identify a key molecular determinant of IFITM3 S-palmitoylation. Trial completion date: Aug 2020 --> May 2022
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
#erbitux (Twitter) - Jan 9, 2021
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, MSi-H Biomarker, IO biomarker: The Evolutionary Landscape of Treatment for BRAF Mutant Metastatic Colorectal Cancer. (Pubmed Central) - Jan 8, 2021
Overall, we identified six emerging strategies: targeting MAPK pathway (monotherapy or combinations), targeting MAPK pathway combined with cytotoxic agents, intensive cytotoxic regimen combinations, targeted agents combined with CPIs, oxidative stress induction, and cytotoxic agents combined with antiangiogenic drugs and CPIs. In the future, the integration of new therapeutic strategies targeting key players in the BRAF oncogenic pathways with current treatment approach based on cytotoxic chemotherapy and surgery is likely to redefine the treatment landscape of these CRC patients.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. (Pubmed Central) - Jan 8, 2021
An extensive translational research program was conducted in the Cetuximab After Progression in KRAS wIld-type colorectal cancer patients-Gruppo Oncologico dell' Italia Meridionale (CAPRI-GOIM) study with the aims of determining which subgroups of patients could benefit from the continuous inhibition of EGFR, from evaluating the role of liquid biopsy-based and its concordance with tissue-based molecular testing, and from investigating novel potential mechanisms of resistance to anti-EGFR therapies. In this review, we summarize the translational and clinical findings of the CAPRI-GOIM program in the context of the current knowledge of therapeutic strategies and of ongoing research on more appropriate uses of anti-EGFR therapies in RAS and BRAF wild-type mCRC patients.
- |||||||||| tremelimumab (CP-675206) / AstraZeneca, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Imfinzi (durvalumab) / AstraZeneca
Clinical, P3 data, Journal: Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. (Pubmed Central) - Jan 7, 2021
P3
There were no statistically significant differences in OS for durvalumab or durvalumab plus tremelimumab versus SoC. However, higher survival rates at 12 to 24 months and response rates demonstrate clinical activity for durvalumab.
- |||||||||| ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: P30CA023074: Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 6, 2021
P2, N=74, Active, not recruiting,
Our retrospective study provides clinical evidence that combined targeted therapy of brigatinib and cetuximab could provide benefit and may potentially be an effective treatment strategy to improve survival outcomes of patients who acquired EGFR T790M/cis-C797S-mediated resistance to osimertinib. Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> May 2021 | Trial primary completion date: Dec 2020 --> May 2021
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Targeting intracranial patient-derived glioblastoma (GBM) with a NIR-I fluorescent immunoconjugate for facilitating its image-guided resection. (Pubmed Central) - Jan 5, 2021
However, we readily observed over an average 6-fold enhancement in the fluorescence emission in the resected intact whole brain ex vivo when performing NIR-I fluorescence imaging (FLI) on the cohort of GBM39 tumor models that were administered the immunoconjugate compared to controls. In all, we laid the initial groundwork for establishing that NIR-I fluorescent immunoconjugates (theranostics) such as cetuximab-IRDye800 can bypass the BBB to visually afford GBM39 tumor tissue differentiation for its image-guided surgical removal.
- |||||||||| Journal: Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews. (Pubmed Central) - Jan 5, 2021
From 113 systematic reviews, we found at least probable systematic review evidence of cardiovascular toxicity for 18 agents, including high- and all-grade hypertension for bevacizumab, ramucirumab, axitinib, cediranib, pazopanib, sorafenib, sunitinib, vandetanib, aflibercept, abiraterone, and enzalutamide, and all-grade hypertension for nintedanib; high- and all-grade arterial thromboembolism (includes cardiac and/or cerebral events) for bevacizumab and abiraterone, high-grade arterial thromboembolism for trastuzumab, and all-grade arterial thromboembolism for sorafenib and tamoxifen; high- and all-grade venous thromboembolism (VTE) for lenalidomide and thalidomide, high-grade VTE for cetuximab and panitumumab, and all-grade VTE for bevacizumab; high- and all-grade left ventricular ejection fraction decline or congestive heart failure for bevacizumab and trastuzumab, and all-grade left ventricular ejection fraction decline/congestive heart failure for pazopanib and sunitinib; and all-grade corrected QT interval prolongation for vandetanib. Our review provides an accessible summary of the cardiovascular toxicity of targeted therapy to assist clinicians and patients when managing cardiovascular health.
- |||||||||| Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (clinicaltrials.gov) - Jan 5, 2021
P1b/2, N=261, Active, not recruiting,
Our review provides an accessible summary of the cardiovascular toxicity of targeted therapy to assist clinicians and patients when managing cardiovascular health. Recruiting --> Active, not recruiting | Trial completion date: Apr 2022 --> Nov 2021 | Trial primary completion date: Apr 2022 --> Nov 2021
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, temuterkib (LY3214996) / Eli Lilly, Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Trial primary completion date, Combination therapy, Metastases: LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 30, 2020
P1b/2, N=46, Recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Apr 2022 --> Nov 2021 | Trial primary completion date: Apr 2022 --> Nov 2021 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Galactose-α-1,3-galactose (alpha-gal) allergy: first pediatric case in a series of patients in Spain. (Pubmed Central) - Dec 30, 2020
A review is also made of the disorder which, due to its variable clinical expression, is referred to as alpha-gal syndrome. The study concludes that a diagnosis of alpha-gal allergy should be considered in patients with urticaria-anaphylaxis of uncertain origin or manifesting after the administration of vaccines or products of bovine/porcine origin.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: DNA biodots based targeted theranostic nanomedicine for the imaging and treatment of non-small cell lung cancer. (Pubmed Central) - Dec 30, 2020
To kill A549 adenocarcinoma cells, the etoposide (control) required significantly (p < 0.05) higher drug concentrations in comparison to non-targeted and; the non-targeted formulation required more concentrations in comparison to targeted liposomes. The in-vivo results demonstrated that CTX-TPGS decorated theranostic liposomes could be a promising carrier for lung theranostics due to their nano-size and selectivity towards EGFR overexpressed cells which provided an improved NSCLC targeted delivery of ETP in comparison to the non-targeted and control formulations.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
Trial completion, Metastases: S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 30, 2020
P2, N=106, Completed,
These results, together with the altered EMT phenotype, may influence the response to cetuximab or cisplatin treatment. Active, not recruiting --> Completed
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Targeting EGFR in Esophagogastric Cancer. (Pubmed Central) - Dec 29, 2020
All three trials were conducted in unselected populations, and therefore, failed to demonstrate clinical benefit. Here, we review previous attempts at targeting EGFR in EGC and potential future biomarkers for targeting this pathway in patients with EGFR-amplified tumors.
- |||||||||| Darzalex IV (daratumumab) / J&J, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Impact of cetirizine versus diphenhydramine on the prevention of chemotherapy-related hypersensitivity reactions and falls () - Dec 26, 2020 - Abstract #ASHP2020ASHP_4041;
The secondary endpoints will include number of patients who were treated with pretreatment agents other than cetirizine on subsequent cycles, adverse events, type and severity of infusion reactions and use of concurrent medications. The data will be analyzed utilizing descriptive statistics, Chi-square test or Fisher’s exact test for nominal data and student’s t-test or Mann Whitney U test for continuous data.
- |||||||||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial completion date, Trial primary completion date, Metastases: ANCHOR-CRC: Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (clinicaltrials.gov) - Dec 21, 2020
P2, N=95, Active, not recruiting,
ExRT was recognized as an effective alternative treatment for locally advanced HNSCC patients who experienced unbearable toxicities caused by non-CTX treatments. Trial completion date: Oct 2020 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Dec 2021
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial completion, Trial completion date, Metastases: Biomarker Directed Treatment in Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 21, 2020
P2, N=47, Completed,
Trial completion date: Oct 2020 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Dec 2021 Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2020
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, BRCA Biomarker, PARP Biomarker: Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models. (Pubmed Central) - Dec 20, 2020
Our results demonstrate that the combination of cetuximab and olaparib with radiation was superior to the combination of any single drug with radiation in terms of induction of unrepaired DNA damage, induction of senescence, apoptosis and clonogenic death, and tumor growth control in mouse xenografts. Combined with our recently published phase I safety data on cetuximab/olaparib/radiation triple combination, the data reported here demonstrate a potential for combining biologically-based therapies that might optimize radiosensitization in HNSCC.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal, Microsatellite instability: Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. (Pubmed Central) - Dec 20, 2020
P3
Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events. (Funded by Merck Sharp and Dohme and by Stand Up to Cancer; KEYNOTE-177 ClinicalTrials.gov number, NCT02563002.).
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, IO Biomarker: Translational Genomics and Recent Advances in Oral Squamous Cell Carcinoma. (Pubmed Central) - Dec 18, 2020
Cetuximab, targeting the epidermal growth factor receptor was approved for the treatment of OSCC in 2006, and remains the only molecular targeted therapy available for OSCC...More recently, with the approval of checkpoint inhibitors for the treatment of cancers including OSCC, genomics studies also dissected the genetic signatures of the immune compartment to delineate immune-active and -exhausted subtypes that could inform on the immune status of OSCC patients and guide the development of novel therapies to improve response to immunotherapy. Taken together, genomics studies are informing on the biology of both the epithelial and stromal compartments underlying OSCC development, and we discuss the opportunities and challenges in using these to derive clinical benefit for OSCC patients.
|
